Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Dermira Stock Is Soaring Today

By Cory Renauer - Nov 8, 2019 at 2:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The demise of a potential competitor gave Dermira investors a reason to cheer.

What happened

Shares of Dermira (DERM), a dermatology-focused biopharmaceutical company, shot up in response to a potential competitor's clinical trial failure. The demise of AnaptysBio's (ANAB 4.92%) experimental eczema treatment has lifted Dermira's stock price 22.1% higher as of 1:55 p.m. on Friday.

So what

Dermira's first drug, Qbrexza, a treatment for excessive underarm sweating, doesn't look as if it will generate enough sales to cover the company's operating expenses. That puts a lot of pressure on an eczema candidate called lebrikizumab that Dermira licensed from Roche (RHHBY 2.34%) a couple of years ago.

Person with a stack of cash making it rain.

Image source: Getty Images.

Etokimab from AnaptysBio doesn't work the same way as lebrikizumab, but it was a potential competitor in an increasingly crowded market for eczema treatments.

Now what

Today's news of a clinical trial flop for etokimab pushes aside a potential competitor that was a long shot anyway. Dermira investors should probably stay focused on the successful launch of Dupixent, a treatment for eczema patients from Regeneron (REGN 0.77%).

Dupixent earned approval in 2017, and sales of the IL-4 inhibitor have already reached a $2.5 billion annualized run rate. Lebrikizumab also inhibits IL-4, but it has a much higher affinity for IL-13 than Dupixent. This difference appears more important than Roche probably imagined, but we still don't have enough data to confidently predict lebrikizumab can outperform Dupixent in the clinic or on the market.

In October, Dermira began a pair of phase 3 trials expected to enroll around 800 adults with moderate to severe eczema. The pivotal study is looking for a high percentage of patients that show minimal symptoms of eczema following 16 weeks of treatment with lebrikizumab. Positive results from this pivotal trial could send Dermira stock screaming higher in the first half of 2021.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dermira, Inc. Stock Quote
Dermira, Inc.
Roche Holding AG Stock Quote
Roche Holding AG
$42.00 (2.34%) $0.96
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$628.71 (0.77%) $4.81
AnaptysBio Stock Quote
$26.23 (4.92%) $1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.